The price for Dosell Consumer is communicated
iZafe Group AB (publ.) (”iZafe” or ”the Company”) announces that the price for the consumer version of Dosell will be SEK 299 per month.
Dosell Consumer is a subscription service without binding period or notice period. A subscription for Dosell Consumer can be subscribed and paid for by, for example, the user directly or relatives to the user. After the customer has purchased the hardware for SEK 499 on apoteket.se, the service offers easy registration with payment solutions directly in the app.
”We are very happy that Dosell, as of Monday October 18, will be made available through apoteket.se for anyone to buy, to a relative or to themself. In an early stage we already have about 20 satisfied users that have tested Dosell before launch. We have visited some of them to hear more about how their everyday life has been made simpler and how their safe use of medication has been facilitated by the help of Dosell. See this video where two of our users and their families describe their experiences. Dosell Consumer is a welcome aid in the home for all people who medicate daily.” says Anders Segerström, CEO of iZafe.
About Dosell Consumer
Dosell Consumer and the Dosell app is a simpler version of iZafe´s professional solution and is adjusted to let users and relatives administrate and ensure correct medication without being dependent on healthcare staff. Both versions of the product are compatible with sachets from every supplier on the market.
Dosell Consumer will be made available for delivery by Apoteket on Monday October 18, 2021, but it is already possible to register interest to ensure availability when Dosell Consumer is launched.
Scandinavian ChemoTech's COO completes his assignment
“Urban has, with his long experience from the industry, been an important asset in the Company's work towards a new strategy and his insights has been essential for the Company's new path choice. I want to thank Urban for a strong effort and wish him luck in his continued career. "- says Mohan Frick...
Scandinavian ChemoTechs COO avslutar sitt uppdrag
”Urban har med sin långa erfarenhet från industrin varit en viktig tillgång i Bolagets arbete med en ny strategi och hans insikter har varit väsentliga för Bolagets nya vägval. Jag vill tacka Urban för en stark insats och önskar honom lycka till i sin fortsatta karriär.” - säger Mohan Frick VD och m...
Klaria Pharma announces approval by the United Stated Patent and Trademark Office of a new patent application covering Naloxone Alginate Film.
With this approval of a new patent, Naloxone Alginate Film will enjoy patent-protected market exclusivity in the United States until 2038. The approval marks the second time the United States Patent Office (USPTO) has approved a compound/Alginate Film combination patent that protects an indivi...
Klaria erhåller besked om godkännande från det Amerikanska patentverket för produktpatent som skyddar Naloxon Alginatfilm fram till år 2038
Med godkännandet av nya patent erhåller Naloxon Alginatfilm patentskyddad marknadsexklusivitet i USA fram till år 2038. Detta är tredje gången som det Amerikanska patentverket godkänner ett kombinationspatent för en specifik substans/Alginatfilm formulerad i Klarias helägda Alginatfilmsteknologi. Go...